BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32967918)

  • 1. Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer.
    Tarazona N; Gimeno-Valiente F; Gambardella V; Huerta M; Roselló S; Zuniga S; Calon A; Carbonell-Asins JA; Fontana E; Martinez-Ciarpaglini C; Eason K; Rentero-Garrido P; Fleitas T; Papaccio F; Moro-Valdezate D; Nyamundanda G; Castillo J; Espí A; Sadanandam A; Roda D; Cervantes A
    ESMO Open; 2020 Sep; 5(5):e000847. PubMed ID: 32967918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification.
    Pilati C; Taieb J; Balogoun R; Marisa L; de Reyniès A; Laurent-Puig P
    Ann Oncol; 2017 May; 28(5):1032-1035. PubMed ID: 28328000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
    Tarazona N; Gimeno-Valiente F; Gambardella V; Zuñiga S; Rentero-Garrido P; Huerta M; Roselló S; Martinez-Ciarpaglini C; Carbonell-Asins JA; Carrasco F; Ferrer-Martínez A; Bruixola G; Fleitas T; Martín J; Tébar-Martínez R; Moro D; Castillo J; Espí A; Roda D; Cervantes A
    Ann Oncol; 2019 Nov; 30(11):1804-1812. PubMed ID: 31562764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative circulating tumor DNA combined with consensus molecular subtypes can better predict outcomes in stage III colon cancers: A prospective cohort study.
    Li Y; Mo S; Zhang L; Ma X; Hu X; Huang D; Lu B; Luo C; Peng H; Cai S; Sheng W; Peng J
    Eur J Cancer; 2022 Jul; 169():198-209. PubMed ID: 35636041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data.
    Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L
    Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Validation Study for Recurrence Risk Stratification of Stage II Colon Cancer Using the 55-Gene Classifier.
    Shinto E; Oki E; Shimokawa M; Yamaguchi S; Ishiguro M; Morita M; Kusumoto T; Tomita N; Hashiguchi Y; Tanaka M; Ohnuma S; Tada S; Matsushima T; Hase K
    Oncology; 2020; 98(8):534-541. PubMed ID: 32235113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
    Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
    Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
    Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
    Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
    Schraa SJ; van Rooijen KL; van der Kruijssen DEW; Rubio Alarcón C; Phallen J; Sausen M; Simmons J; Coupé VMH; van Grevenstein WMU; Elias S; Verkooijen HM; Laclé MM; Bosch LJW; van den Broek D; Meijer GA; Velculescu VE; Fijneman RJA; Vink GR; Koopman M;
    BMC Cancer; 2020 Aug; 20(1):790. PubMed ID: 32819390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study.
    Øgaard N; Reinert T; Henriksen TV; Frydendahl A; Aagaard E; Ørntoft MW; Larsen MØ; Knudsen AR; Mortensen FV; Andersen CL
    Eur J Cancer; 2022 Mar; 163():163-176. PubMed ID: 35074652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of postoperative circulating tumour DNA to predict early recurrence in patients with stage I-III right-sided colon cancer: prospective observational study.
    Lygre KB; Forthun RB; Høysæter T; Hjelle SM; Eide GE; Gjertsen BT; Pfeffer F; Hovland R
    BJS Open; 2024 Jan; 8(1):. PubMed ID: 38242575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
    Dalerba P; Sahoo D; Paik S; Guo X; Yothers G; Song N; Wilcox-Fogel N; Forgó E; Rajendran PS; Miranda SP; Hisamori S; Hutchison J; Kalisky T; Qian D; Wolmark N; Fisher GA; van de Rijn M; Clarke MF
    N Engl J Med; 2016 Jan; 374(3):211-22. PubMed ID: 26789870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry.
    Li X; Larsson P; Ljuslinder I; Ling A; Löfgren-Burström A; Zingmark C; Edin S; Palmqvist R
    Pathol Res Pract; 2021 Apr; 220():153379. PubMed ID: 33721619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating DNA in the neoadjuvant setting of early stage colon cancer.
    Bregni G; Pretta A; Senti C; Acedo Reina E; Vandeputte C; Trevisi E; Gkolfakis P; Kehagias P; Deleporte A; Van Laethem JL; Vergauwe P; Van den Eynde M; Deboever G; Janssens J; Demolin G; Holbrechts S; Clausse M; De Grez T; Peeters M; D'Hondt L; Geboes K; Besse-Hammer T; Rothé F; Flamen P; Hendlisz A; Sclafani F
    Acta Oncol; 2022 Oct; 61(10):1223-1229. PubMed ID: 35866544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study.
    Tie J; Cohen JD; Wang Y; Li L; Christie M; Simons K; Elsaleh H; Kosmider S; Wong R; Yip D; Lee M; Tran B; Rangiah D; Burge M; Goldstein D; Singh M; Skinner I; Faragher I; Croxford M; Bampton C; Haydon A; Jones IT; S Karapetis C; Price T; Schaefer MJ; Ptak J; Dobbyn L; Silliman N; Kinde I; Tomasetti C; Papadopoulos N; Kinzler K; Volgestein B; Gibbs P
    Gut; 2019 Apr; 68(4):663-671. PubMed ID: 29420226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.
    Tie J; Wang Y; Tomasetti C; Li L; Springer S; Kinde I; Silliman N; Tacey M; Wong HL; Christie M; Kosmider S; Skinner I; Wong R; Steel M; Tran B; Desai J; Jones I; Haydon A; Hayes T; Price TJ; Strausberg RL; Diaz LA; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Sci Transl Med; 2016 Jul; 8(346):346ra92. PubMed ID: 27384348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.
    Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W
    J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
    Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
    Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases.
    Reinert T; Petersen LMS; Henriksen TV; Larsen MØ; Rasmussen MH; Johansen AFB; Øgaard N; Knudsen M; Nordentoft I; Vang S; Krag SRP; Knudsen AR; Mortensen FV; Andersen CL
    Int J Cancer; 2022 May; 150(9):1537-1548. PubMed ID: 34994972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.